| abstract |
The present invention relates to novel compounds that mimic interleukin-1 stone-converting enzyme (ICE) inhibitors. The ICE inhibitors of the present invention are characterized by a unique structural and physico-chemical hypotension. The present invention also encompasses such compounds in pharmaceutical compositions. The compounds of the present invention and the pharmaceutical composition are particularly suitable for inhibiting ICE activity, and are therefore preferably useful for diseases mediated by IL-1, apoptosis, IGIF, and IFN-g, obstructive diseases, booster diseases, destructive tubular disorders, proliferative disorders, infectious diseases, degenerative diseases, and as an anticancer agent. In addition, methods for the preparation of N-acylamine compounds are included within the scope of the invention. ŕ |